27,661 Shares in HealthEquity, Inc. $HQY Purchased by Paralel Advisors LLC

Paralel Advisors LLC purchased a new stake in HealthEquity, Inc. (NASDAQ:HQY) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 27,661 shares of the company’s stock, valued at approximately $2,498,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in HealthEquity during the 2nd quarter worth approximately $1,018,621,000. William Blair Investment Management LLC bought a new position in shares of HealthEquity in the fourth quarter valued at approximately $169,956,000. Wasatch Advisors LP lifted its holdings in shares of HealthEquity by 10.5% in the second quarter. Wasatch Advisors LP now owns 7,960,735 shares of the company’s stock valued at $719,014,000 after purchasing an additional 757,801 shares in the last quarter. Norges Bank purchased a new position in shares of HealthEquity during the fourth quarter valued at approximately $66,927,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of HealthEquity during the second quarter valued at approximately $60,177,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on HQY. Wells Fargo & Company set a $111.00 price target on HealthEquity in a report on Monday, June 1st. BTIG Research raised their price objective on HealthEquity from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Barrington Research reaffirmed an “outperform” rating and set a $110.00 price objective on shares of HealthEquity in a report on Friday, May 22nd. Wall Street Zen lowered shares of HealthEquity from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Royal Bank Of Canada raised their price target on shares of HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a research report on Wednesday, June 3rd. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, HealthEquity presently has a consensus rating of “Moderate Buy” and an average target price of $110.93.

HealthEquity Price Performance

Shares of NASDAQ HQY opened at $104.27 on Friday. The company has a market capitalization of $8.72 billion, a PE ratio of 39.05, a PEG ratio of 1.75 and a beta of 0.21. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46. The stock’s 50 day moving average price is $96.30 and its 200-day moving average price is $87.07. HealthEquity, Inc. has a twelve month low of $72.76 and a twelve month high of $107.62.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Thursday, May 28th. The company reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.13. The company had revenue of $354.64 million during the quarter, compared to the consensus estimate of $352.02 million. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.HealthEquity’s revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. On average, equities analysts anticipate that HealthEquity, Inc. will post 3.92 EPS for the current year.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, EVP Michael Henry Fiore sold 3,142 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $95.00, for a total value of $298,490.00. Following the completion of the transaction, the executive vice president owned 59,113 shares in the company, valued at $5,615,735. This represents a 5.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gayle Furgurson Wellborn sold 2,439 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $90.00, for a total value of $219,510.00. Following the sale, the director directly owned 19,733 shares of the company’s stock, valued at approximately $1,775,970. This represents a 11.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 17,905 shares of company stock worth $1,651,280 in the last quarter. 1.60% of the stock is currently owned by company insiders.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.